ANGLE plc (GB:AGL) has released an update.
ANGLE plc, a pioneering liquid biopsy company, showcased its advanced cancer analysis technologies at the EACR 2024 Congress, presenting two posters on its Parsortix system’s capabilities in detecting mutations in circulating tumor cells (CTCs) and DNA (ctDNA) and monitoring DNA damage response (DDR) in real-time treatment assessment. The studies emphasized the enhanced mutation detection and personalized treatment insights gained from analyzing both CTCs and ctDNA, as well as the potential of their DDR assay in evaluating cancer therapies. The company’s participation underscores its commitment to advancing cancer patient care through innovative diagnostic solutions.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.
